These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 34607233)

  • 21. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
    Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. (3R)-5,6,7-trihydroxy-3-isopropyl-3-methylisochroman-1-one enhanced the therapeutic efficacy of anti-PD1 antibody through inhibiting PI3Kδ/γ.
    Cao L; Dai C; Qin R; Guo Y; Liu J
    Immunopharmacol Immunotoxicol; 2019 Dec; 41(6):599-606. PubMed ID: 31691624
    [No Abstract]   [Full Text] [Related]  

  • 23. Myeloid-derived Suppressor Cells Elimination by 5-Fluorouracil Increased Dendritic Cell-based Vaccine Function and Improved Immunity in Tumor Mice.
    Khosravianfar N; Hadjati J; Namdar A; Boghozian R; Hafezi M; Ashourpour M; Kheshtchin N; Banitalebi M; Mirzaei R; Razavi SA
    Iran J Allergy Asthma Immunol; 2018 Feb; 17(1):47-55. PubMed ID: 29512369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.
    Gao W; Zhang X; Yang W; Dou D; Zhang H; Tang Y; Zhong W; Meng J; Bai Y; Liu Y; Yang L; Chen S; Liu H; Yang C; Sun T
    J Immunother Cancer; 2019 Aug; 7(1):231. PubMed ID: 31462297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional tumor specific CD8 + T cells in spleen express a high level of PD-1.
    Wang Z; Chen T; Lin W; Zheng W; Chen J; Huang F; Xie X
    Int Immunopharmacol; 2020 Mar; 80():106242. PubMed ID: 32014811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crosslinking of Ly6a metabolically reprograms CD8 T cells for cancer immunotherapy.
    Maliah A; Santana-Magal N; Parikh S; Gordon S; Reshef K; Sade Y; Khateeb A; Richter A; Gutwillig A; Parikh R; Golan T; Krissi M; Na M; Binshtok G; Manich P; Elkoshi N; Grisaru-Tal S; Zemser-Werner V; Brenner R; Vaknine H; Nizri E; Moyal L; Amitay-Laish I; Rosemberg L; Munitz A; Kronfeld-Schor N; Shifrut E; Kobiler O; Madi A; Geiger T; Carmi Y; Levy C
    Nat Commun; 2024 Sep; 15(1):8354. PubMed ID: 39333093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity.
    Wang Z; Xu F; Hu J; Zhang H; Cui L; Lu W; He W; Wang X; Li M; Zhang H; Xiong W; Xie C; Liu Y; Zhou P; Liu J; Huang P; Qin XF; Xia X
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.
    Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of exercise and anti-PD-1 on the tumour microenvironment.
    Buss LA; Williams T; Hock B; Ang AD; Robinson BA; Currie MJ; Dachs GU
    Immunol Lett; 2021 Nov; 239():60-71. PubMed ID: 34480981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
    Tsukamoto H; Kubota K; Shichiku A; Maekawa M; Mano N; Yagita H; Ohta S; Tomioka Y
    Immunology; 2019 Oct; 158(2):136-149. PubMed ID: 31515801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
    Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
    Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression.
    Hwang HS; Cherukula K; Bang YJ; Vijayan V; Moon MJ; Thiruppathi J; Puth S; Jeong YY; Park IK; Lee SE; Rhee JH
    Cells; 2020 Nov; 9(11):. PubMed ID: 33171765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neogambogic acid enhances anti-PD-1 immunotherapy efficacy by attenuating suppressive function of MDSCs in pancreatic cancer.
    Xun J; Jiang X; Liu B; Hu Z; Liu J; Han Y; Gao R; Zhang H; Yang S; Yu X; Wang X; Yan C; Zhang Q
    Int Immunopharmacol; 2024 Sep; 139():112696. PubMed ID: 39018692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiofrequency radiation reshapes tumor immune microenvironment into antitumor phenotype in pulmonary metastatic melanoma by inducing active transformation of tumor-infiltrating CD8
    Jiao JZ; Zhang Y; Zhang WJ; He MD; Meng M; Liu T; Ma QL; Xu Y; Gao P; Chen CH; Zhang L; Pi HF; Deng P; Wu YZ; Zhou Z; Yu ZP; Deng YC; Lu YH
    Acta Pharmacol Sin; 2024 Jul; 45(7):1492-1505. PubMed ID: 38538718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy.
    Schoonderwoerd MJA; Koops MFM; Angela RA; Koolmoes B; Toitou M; Paauwe M; Barnhoorn MC; Liu Y; Sier CFM; Hardwick JCH; Nixon AB; Theuer CP; Fransen MF; Hawinkels LJAC
    Clin Cancer Res; 2020 Jul; 26(14):3831-3842. PubMed ID: 32332012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prophylactic DNA vaccine targeting Foxp3
    Namdar A; Mirzaei R; Memarnejadian A; Boghosian R; Samadi M; Mirzaei HR; Farajifard H; Zavar M; Azadmanesh K; Elahi S; Noorbakhsh F; Rezaei A; Hadjati J
    Cancer Immunol Immunother; 2018 Mar; 67(3):367-379. PubMed ID: 29124314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8
    Song F; Hu B; Liang XL; Cheng JW; Wang CG; Wang PX; Wang TL; Tang PJ; Sun HX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
    Clin Transl Med; 2024 Aug; 14(8):e1738. PubMed ID: 39095323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy.
    Tähtinen S; Feola S; Capasso C; Laustio N; Groeneveldt C; Ylösmäki EO; Ylösmäki L; Martins B; Fusciello M; Medeot M; Tagliamonte M; Chiaro J; Hamdan F; Peltonen K; Ranki T; Buonaguro L; Cerullo V
    Cancer Res; 2020 Jun; 80(12):2575-2585. PubMed ID: 32107211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.